Elios A Prospective, Randomized, Blinded, Placebo-Controlled, Phase IIb Trial Of An Autologous Tumor Lysate (Tl) + Yeast Cell Wall Particles (Ycwp) + Dendritic Cells (Dc) Vaccine Vs Unloaded Ycwp + Dc In Stage III And Stage Iv (Resected) Melanoma To Preve
Posted Date: May 15, 2019
- Investigator: Jeffrey Sussman
- Specialties: Cancer, Oncology, Skin Cancer
- Type of Study: Drug
The goal of this study is to determine 24-month disease-free survival (DFS) in vaccinated (TLPLDC) vs control patients, as well as assess the safety of the vaccine per CTCAEv4.03.
Criteria:
To Be Eligible: Patients Must Be 18+ Years Of Age, Clinically Disease Free After Surgery, No Immune Deficiency Disease, Pregnancy, Or Breastfeeding
Keywords:
Melanoma, Skin Cancer, Melanoma
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com